Key features and details
- Mouse monoclonal [B-E8] to IL-6
- Suitable for: IHC-Fr, ELISA, Neutralising
- Reacts with: Human
- Isotype: IgG1
Product nameAnti-IL-6 antibody [B-E8]
See all IL-6 primary antibodies
DescriptionMouse monoclonal [B-E8] to IL-6
Tested applicationsSuitable for: IHC-Fr, ELISA, Neutralisingmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Human
Full length protein corresponding to Human IL-6.
General notesStorage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Concentration information loading...
PurityIon Exchange Chromatography
Purification notesPurified IgG prepared by ion exchange chromatography from tissue culture supernatant.
Our Abpromise guarantee covers the use of ab11449 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-Fr||Use at an assay dependent concentration.|
|ELISA||Use at an assay dependent concentration.|
|Neutralising||Use at an assay dependent concentration. 20pg neutralizes activity of 1U of IL6. For this application removal of azide is recommended.|
FunctionCytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
Involvement in diseaseGenetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
Sequence similaritiesBelongs to the IL-6 superfamily.
modificationsN- and O-glycosylated.
- Information by UniProt
- Interleukin BSF 2 antibody
- B cell differentiation factor antibody
- B cell stimulatory factor 2 antibody
ab11449 has been referenced in 5 publications.
- Zhao D et al. Human neural stem cell tropism to metastatic breast cancer. Stem Cells 30:314-25 (2012). PubMed: 22084033
- Cejková J et al. Favorable effects of trehalose on the development of UVB-mediated antioxidant/pro-oxidant imbalance in the corneal epithelium, proinflammatory cytokine and matrix metalloproteinase induction, and heat shock protein 70 expression. Graefes Arch Clin Exp Ophthalmol 249:1185-94 (2011). IHC-Fr ; Rabbit . PubMed: 21494875
- Zenkel M et al. Proinflammatory cytokines are involved in the initiation of the abnormal matrix process in pseudoexfoliation syndrome/glaucoma. Am J Pathol 176:2868-79 (2010). IHC-Fr ; Human . PubMed: 20395431
- Kube D et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 98:762-70 (2001). Neutralising ; Human . PubMed: 11468177
- Klein B et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1198-204 (1991). Neutralising ; Human . PubMed: 1715218